The pharmaceutical landscape has been dramatically reshaped by a new class of drugs, glucagon-like peptide 1 (GLP-1) analogs, which include household names like semaglutide (marketed as Wegovy and Ozempic) and liraglutide (Saxenda). These "blockbuster" medications have revolutionized the treatment of obesity and type 2 diabetes, demonstrating profound effects on weight loss and glycemic control. However, despite their widespread use and significant impact, a fundamental question has persisted among researchers and clinicians: where precisely do these powerful peptides exert their influence within the intricate architecture of the brain, and critically, do these neural pathways differ between females and males?<\/p>\n
A pioneering study, recently published in Brain Medicine<\/em> by researchers from the Icahn School of Medicine at Mount Sinai, has begun to unravel this mystery. Led by Vitaly Ryu, Anisa Gumerova, Georgii Pevnev, Tony Yuen, and senior author Mone Zaidi, the research team constructed what is believed to be the first comprehensive sex-specific atlas of GLP-1 expression in the murine brain at single-transcript resolution. Their meticulous mapping across 25 distinct brain nuclei, subnuclei, and regions in both sexes has revealed "startling" geographic differences, providing a crucial neuroanatomical foundation for understanding the observed variations in drug efficacy and opening new avenues for sex-specific therapeutic interventions.<\/p>\n The Rise of GLP-1 Analogs: A Paradigm Shift in Metabolic Health<\/strong><\/p>\n The journey of GLP-1 analogs from scientific discovery to medical phenomenon spans several decades. The glucagon-like peptide-1 hormone itself was first identified in the 1980s, recognized for its role in regulating glucose homeostasis by enhancing insulin secretion in a glucose-dependent manner (the "incretin effect"). Early research focused on its potential for diabetes treatment, leading to the development of the first GLP-1 receptor agonists in the mid-2000s. Exenatide, approved in 2005, was among the first. Subsequent advancements brought longer-acting versions like liraglutide (Saxenda, approved for obesity in 2014) and semaglutide (Ozempic for diabetes in 2017, and Wegovy for obesity in 2021), which have demonstrated unprecedented weight loss capabilities, often exceeding 15% of body weight in clinical trials.<\/p>\n The economic and public health implications of these drugs are immense. Obesity rates have soared globally, with over 40% of adults in the United States classified as obese, according to the Centers for Disease Control and Prevention. Type 2 diabetes affects more than 37 million Americans. These conditions carry substantial healthcare costs and significantly reduce quality of life. GLP-1 analogs offer a powerful tool in combating this crisis, not only by promoting weight loss and blood sugar control but also by demonstrating cardiovascular benefits. The market for these drugs is projected to reach hundreds of billions of dollars annually, underscoring their transformative potential.<\/p>\n Despite their success, a persistent observation in clinical practice has been the differential response between sexes. Females often report stronger appetite suppression and experience greater weight loss compared to males on GLP-1 therapies. While various physiological factors have been hypothesized, a detailed understanding of the neural underpinnings of this disparity remained elusive until now.<\/p>\n A New Map for the Brain: Unveiling Sex-Specific GLP-1 Geography<\/strong><\/p>\n "We set out to build a resource that the field has needed for a long time," stated Mone Zaidi, the study’s senior author and a distinguished professor at the Icahn School of Medicine at Mount Sinai. "GLP-1 analogs are among the most impactful drug classes to emerge in decades, yet we have lacked a detailed, sex-specific map of where GLP-1 is actually expressed in the brain. This atlas provides that foundation."<\/p>\n To construct this intricate map, the research team employed RNAscope, a cutting-edge technique renowned for its ability to detect single mRNA transcripts with exceptional sensitivity and specificity. This method overcomes previous limitations in detecting GLP-1, which is produced in relatively small quantities in the brain and rapidly degraded, making it historically challenging to pinpoint its exact locations. The RNAscope approach utilizes approximately 20 pairs of transcript-specific double Z-probes that hybridize to 5-micrometer-thick whole brain sections, offering a level of detail unattainable by older analytical methods.<\/p>\n The team meticulously mapped Glp1<\/em> expression across the entire mouse brain in three female and three male animals. Two independent observers, blinded to the sex of the samples, manually counted transcripts in every tenth section using systematic counting, ensuring robust inter-rater reliability. Probe specificity was rigorously validated through positive staining in known GLP-1 producing organs like the small intestine and pancreas, as well as the medullary nucleus of the solitary tract, while absent staining in the kidney served as a negative control. The resulting compendium offers an unprecedented look into the neural distribution of GLP-1.<\/p>\n Key Findings: Profound Differences in the Hindbrain and Olfactory System<\/strong><\/p>\n The study identified Glp1<\/em> expression across multiple major brain divisions, including the medulla, olfactory bulb, midbrain and pons, hippocampus, hypothalamus, thalamus, and the ependymal layer of the third ventricle. In both sexes, the medulla and olfactory bulb harbored the highest total counts of Glp1<\/em>. However, the patterns within these regions were far from symmetrical between females and males.<\/p>\n The Hindbrain: A Nexus of Sex-Biased Expression<\/strong> Crucially, Glp1<\/em> densities and the total number of Glp1<\/em>-expressing neurons in the ROb, SolV, and ventrolateral part of the solitary tract (SolVL) were consistently higher in females compared to males. The numbers of Glp1<\/em>-expressing neurons were statistically significantly higher in the SolV of females (P = 0.034), with a similar trend observed in the SolVL (P = 0.069).<\/p>\n Vitaly Ryu, co-first author and lead designer of the experiments, highlighted the significance: "What struck us was not just where we found GLP-1 expression, but the degree to which the pattern diverged between females and males in specific hindbrain subnuclei. Several medullary nuclei displayed expression in only one sex, which opens entirely new questions about how GLP-1 circuits operate differently in the female and male brain."<\/p>\n Indeed, several medullary nuclei exhibited what the authors termed "sex-biased expression." For instance, Glp1<\/em> transcripts were detected exclusively in the ambiguus nucleus, tectospinal tract, ventral cochlear nucleus (posterior part), and cuneate nucleus of females. In contrast, the dorsomedial spinal trigeminal nucleus, intercalated nucleus of the medulla, paramedian reticular nucleus, SolCe, and spinal trigeminal nucleus (caudal part) showed expression only in males. The ambiguus nucleus in females and the SolCe in males stood out as the nuclei with the highest Glp1<\/em> expression in a single sex. While acknowledging that very low-frequency events might be missed, these findings are robust enough to generate significant hypotheses for future research.<\/p>\n The Olfactory Bulb: A Metabolic Surprise<\/strong> This observation takes on deeper meaning when considering existing knowledge. GLP-1-releasing interneurons have been previously identified in the olfactory bulb of rodents, where they are thought to modulate mitral cell excitability in response to food intake, contributing to an anorexigenic (appetite-suppressing) action. Furthermore, recent research has shown that in lean and diet-induced obese male mice, the mere smell of food can induce cephalic phase insulin release \u2013 a pre-emptive insulin surge in anticipation of food. Conversely, females are known to possess enhanced olfactory abilities, influenced by the presence and modulatory effects of estrogen receptors within the olfactory bulb.<\/p>\n The authors propose a fascinating compensatory relationship: given that GLP-1 generally has stronger effects on appetite suppression and weight loss in females, it is plausible that lower Glp1<\/em> densities in the GrO of females are offset by sufficient and necessary estrogen actions on appetite regulation via the olfactory system. The higher Glp1<\/em> expression in the GrO of males could contribute to higher insulin levels compared with females, potentially explaining why male mice are more prone to developing hyperinsulinemia on a high-fat diet. This tantalizing hypothesis suggests that GrO-derived GLP-1 might underlie a sex-specific amplification of olfactory-driven insulin signaling in males, making them more susceptible to metabolic dysregulation triggered by food cues.<\/p>\n A Symphony of Peptides: GLP-1 in a Broader Context<\/strong><\/p>\n The study also reinforces the understanding that GLP-1 does not operate in isolation but rather as part of a complex, sexually dimorphic network of peptide systems that regulate ingestive and reward behaviors. Under unstressed conditions, females typically exhibit lower levels of orexigenic (appetite-stimulating) neuropeptide Y (NPY) and fewer NPY-expressing neurons in the hypothalamus than males. Conversely, females possess more anorexigenic pro-opiomelanocortin (POMC) neurons, which also display higher neural activities. Estrogen receptor alpha, expressed by POMC neurons, has been shown to suppress food intake specifically in female mice, suggesting a crucial interplay between estrogen-driven POMC and GLP-1 mechanisms in regulating appetite.<\/p>\n Leptin signaling, another key hormone in appetite regulation, also exhibits sexual dimorphism, and it stimulates GLP-1 receptor-expressing neurons in the solitary tract, contributing additively to food intake suppression. The orexigenic gastric hormone ghrelin, which counterbalances leptin, is known to interact with GLP-1 through a gating mechanism on vagal neurons. Furthermore, GLP-1 neuronal axon terminals in the ROb are in close apposition to serotonergic neurons in the parapyramidal region, implying projections to brainstem areas implicated in autonomic appetite suppression.<\/p>\n The portrait emerging from this research is one of a sophisticated, coordinated conversation among multiple peptidergic systems, with each component intricately inflected by sex. This integrated view is critical for developing therapies that consider the full biological context.<\/p>\n Beyond Metabolism: Psychiatric and Neurological Implications<\/strong><\/p>\n While the most prominent applications of GLP-1 analogs have been in metabolic health, emerging evidence points to their potential in treating a range of psychiatric and neurological conditions. The Mount Sinai study provides crucial neuroanatomical support for these broader applications by detecting Glp1<\/em> expression in brain regions associated with reward, motivation, and memory.<\/p>\n Specifically, Glp1<\/em> expression was found in the midbrain and pons (including the interfascicular nucleus, ventral tegmental area, paranigral nucleus, and interpeduncular fossa), hippocampus (granular layer of the dentate gyrus), hypothalamus (posterior hypothalamic area and lateral hypothalamus), thalamus (dorsal lateral geniculate nucleus), and the ependymal layer of the third ventricle.<\/p>\n Significantly, the ventral tegmental area (VTA), a brain region central to reward processing and implicated in addiction, showed Glp1<\/em> expression exclusively in females. Conversely, the lateral hypothalamus, a key player in motivated behavior and feeding, exhibited expression only in males. These sex-specific distributions suggest that GLP-1’s impact on reward circuits and motivated behaviors could differ profoundly between sexes, potentially explaining why females and males might experience different responses to GLP-1-based treatments for conditions like addiction or depression.<\/p>\n "The implications extend well beyond metabolism," Zaidi affirmed. "With growing evidence that GLP-1 analogs may help prevent or treat cognitive decline, and given that we can detect Glp1<\/em> transcripts in Alzheimer’s vulnerable regions in the mouse brain, this atlas should help guide future investigations into how GLP-1 acts on neuroinflammation, neuronal degeneration, and memory loss." The presence of Glp1<\/em> in the hippocampus, a region vital for memory formation and highly vulnerable in Alzheimer’s disease, suggests a direct role for GLP-1 in neuroprotection and cognitive function, opening exciting avenues for future research into sex-specific neurodegenerative disease treatments.<\/p>\n Towards Precision Medicine: Guiding Future Therapies<\/strong><\/p>\n The findings of this atlas provide a critical "map" that helps explain why females often experience stronger appetite suppression and weight loss on GLP-1 analogs. The higher density of GLP-1 "docking stations" in key hindbrain appetite-control centers in females suggests a louder and more effective signaling pathway for satiety, leading to a more pronounced response to the drugs that mimic this hormone. For males, the higher GLP-1 levels in the olfactory bulb and its potential link to olfactory-driven insulin spikes offer a unique perspective on their metabolic vulnerabilities and potential therapeutic targets.<\/p>\n This research lays a robust foundation for the development of more precise and effective GLP-1-based therapies. By understanding the sex-specific neuroanatomical distribution of GLP-1, researchers can design drugs or treatment strategies that specifically target these pathways, potentially leading to individualized medicine approaches. For instance, future GLP-1 analogs might be tailored to address female-pattern depression or male-pattern addiction, or even developed as a preventative shield against Alzheimer’s disease, leveraging the distinct neural expressions observed.<\/p>\n The translational relevance of these findings is bolstered by the observation that the expression pattern of preproglucagon neurons in the brain is highly conserved between rodents and nonhuman primates, suggesting that these sex-specific differences are likely to be present in humans as well.<\/p>\n Acknowledged Limitations and Future Directions<\/strong><\/p>\n The authors are transparent about the inherent limitations of this pioneering work. The relatively small sample size of three animals per sex, while standard for such detailed anatomical mapping, naturally limits statistical power, particularly for detecting very low-abundance or regionally sparse Glp1<\/em>-expressing cells. The absence of estrous cycle staging for female animals could introduce variability within the female group, though it is unlikely to alter the main qualitative patterns reported.<\/p>\n Furthermore, while RNAscope definitively identifies Glp1<\/em> gene expression, it does not directly assess peptide synthesis, release, or functional engagement at the cellular or circuit level. Therefore, conclusions regarding direct circuit-level or behavioral effects remain inferential and require further functional studies. The atlas is optimized for detecting moderate-to-high Glp1<\/em> expression patterns and possesses limited statistical power to definitively determine presence or absence in regions characterized by extremely sparse transcript abundance.<\/p>\n Despite these caveats, the study represents a significant leap forward. This atlas was not built to close a door, but rather to open many new ones. The comprehensive mapping of Glp1<\/em> at the single-transcript level in the murine brain provides an invaluable resource for identifying and interrogating new functional GLP-1 circuits. It encourages further research into the coordinated interplay with other peptides that regulate food intake and other behaviors, and it will undoubtedly guide the development of more precise and effective GLP-1-based therapies.<\/p>\n Somewhere between the raphe obscurus nucleus of a female mouse and the granular cell layer of a male, between the powerful peptide that signals satiety and the intricate hormonal milieu that modulates its effects, lies a critical piece of the puzzle that clinicians prescribing semaglutide have been assembling by intuition. Now, armed with this detailed atlas, the journey toward more targeted and personalized metabolic and neurological treatments has a much clearer map.<\/p>\n Q: Why do women seem to lose more weight on Ozempic than men?<\/strong> Q: Can a smell make you gain weight?<\/strong> Q: Are these drugs for more than just weight loss?<\/strong> Author:<\/strong> Ma-Li Wong Original Research:<\/strong> Open access. The pharmaceutical landscape has been dramatically reshaped by a new class of drugs, glucagon-like peptide 1 (GLP-1) analogs, which include household names like semaglutide (marketed as Wegovy and Ozempic) and…<\/p>\n","protected":false},"author":1,"featured_media":763,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[41,43,42,44,45],"class_list":["post-764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-brain-science","tag-cognitive-science","tag-neurology","tag-neuroplasticity","tag-research"],"_links":{"self":[{"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/posts\/764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/comments?post=764"}],"version-history":[{"count":0,"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/posts\/764\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/media\/763"}],"wp:attachment":[{"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/media?parent=764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/categories?post=764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forgetnow.com\/index.php\/wp-json\/wp\/v2\/tags?post=764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nWithin the hindbrain, a region critical for autonomic functions, including appetite regulation and satiety, the differences were particularly pronounced. In females, the highest Glp1<\/em> densities were found in the raphe obscurus nucleus (ROb), the ventral part of the nucleus of the solitary tract (SolV), and the medial part of the solitary tract (SolM). Conversely, in males, the highest densities appeared in the central (SolCe), intermediate (SolIM), and medial subnuclei of the solitary tract.<\/p>\n
\nPerhaps one of the most unexpected revelations emerged from the olfactory bulb, the brain region responsible for processing smells. The study found that Glp1<\/em> density was significantly greater in the olfactory bulb of males compared with females (P = 0.024). This difference was primarily driven by markedly higher Glp1<\/em> densities in the granular cell layer (GrO) of males (P = 0.031).<\/p>\nKey Questions Answered:<\/h3>\n
\nA:<\/strong> This study provides a neuroanatomical explanation. Researchers found that females exhibit a significantly higher density of GLP-1\u2014the hormone mimicked by these drugs\u2014in key hindbrain regions responsible for appetite control, such as the raphe obscurus nucleus and specific parts of the solitary tract. This greater abundance of "docking stations" for GLP-1 in female brains means the drug’s satiety signal may be amplified, leading to stronger appetite suppression and more effective weight loss compared to males.<\/p>\n
\nA:<\/strong> For males, this study suggests it might be easier. The research revealed that males have higher GLP-1 levels in the granular cell layer of the olfactory bulb, the brain’s smell processing center. This higher GLP-1 expression in the male olfactory system could trigger a unique "insulin spike" in response to food odors alone. This mechanism may contribute to why male mice are more prone to developing insulin issues on high-fat diets, suggesting a direct link between olfactory cues, GLP-1 signaling, and metabolic health in a sex-specific manner.<\/p>\n
\nA:<\/strong> Absolutely. The study detected Glp1<\/em> expression in brain areas traditionally linked to addiction (ventral tegmental area), depression (lateral hypothalamus), and memory (hippocampus). Notably, Glp1<\/em> expression in the ventral tegmental area was exclusive to females, while in the lateral hypothalamus, it was exclusive to males. These sex-specific distributions open up significant possibilities for future research into GLP-1 analogs designed to treat sex-specific patterns of addiction or depression. Furthermore, the presence of Glp1<\/em> in Alzheimer’s-vulnerable regions suggests potential for these drugs to protect against cognitive decline, neuroinflammation, and neuronal degeneration.<\/p>\nAbout this neuropharmacology research news<\/h3>\n
\nSource:<\/strong> Genomic Press
\nContact:<\/strong> Ma-Li Wong \u2013 Genomic Press
\nImage:<\/strong> The image is credited to Neuroscience News<\/p>\n
\n\u201cAtlas of GLP-1 expression in the mouse brain: Neuroanatomical basis for metabolic and psychiatric effects\u201d by Ryu V, Gumerova A, Pevnev G, Yuen T, Zaidi M. Brain Medicine<\/em>
\nDOI:10.61373\/bm026a.0006<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"